attomarker

Partner

At Attomarker, we partner with a diverse range of organisations to provide rapid, blood testing technology to support data-driven decisions for personalised patient care.

Healthcare Providers and Distributers

Partner with Attomarker to bring groundbreakingly biomarker technology to your patients. Together, we can achieve earlier diagnoses, better patient outcomes, and a healthier future for all.

Attomarker is seeking high quality, healthcare providers and distributors globally with access to primary care, specialists clinics and hospitals, including emergency and ITU environments, who wish to evaluate the opportunity to distribute Attomarker products. The Attomarker distribution opportunity is significant and constantly expanding. Consequently, we have a rigorous two-way evaluation process to ensure quality representation of this ground-breaking technology.

7 reasons

COVID Antibody Spectrum Test Providers

Birmingham / London / Leeds

London

Dundee

Charities and Patient Groups

Attomarker collaborates with charities and patient groups on advancing healthcare solutions, particularly in the areas of diagnostic testing in long COVID, Liver function, Human Infection and fertility. By partnering we can help drive awareness, support patient access to critical tests, and contribute to innovative research that aims to improve patient care and outcomes. Additionally, Attomarker provides the potential for these groups to access valuable evidence and insights that can inform their advocacy and healthcare initiatives.

Pharma and Life Sciences

Attomarker provides pharmaceutical companies and life sciences organisations with advanced diagnostic technologies and data insights to enhance drug development and clinical trials, improving patient monitoring, biomarker identification, and treatment response.

Are You Building Your Own Test?

We work with organisations to support the creation of alternative tests using our state of the art facilities.

Investors

We are keen to hear from potential investors, individual or institutions, who would like to be kept informed of investment rounds and opportunities as they arise.

Philanthropy

Attomarker’s collaboration with philanthropists, including over 1,000 donors to the University of Exeter Emergency Appeal, enabled the initial SARS-CoV-2 research and the COVID antibody trial in London, conducted by Professor Andrew Shaw Research Group on the Attomarker platform in collaboration with St Thomas’ Hospital. By supporting Attomarker, you can play a pivotal role in advancing critical research like the initial SARS-CoV-2.

Please get in touch to discuss how Attomarker can support your work